Answers are grounded in this paper and cite their sources.
Development of novel therapeutics for treatment of Duchenne muscular dystrophy (DMD) has led to clinical trials that include pulmonary endpoints that allow assessment of respiratory muscle status, especially in nonambulatory subjects. Parent Project Muscular Dystrophy (PPMD) convened a workshop in Bethesda, Maryland, on April 14 and 15, 2016, to summarize published respiratory data in DMD and give guidance to clinical researchers assessing the effect of interventions on pulmonary outcomes in DMD.
No takes yet. Share an insight, caveat, or question.
Finder et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: